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Abstract
Background: Mycobacterium abscessus (M. abscessus) pulmonary disease is a refractory chronic infectious disease.
Options for treating M. abscessus pulmonary disease are limited, especially in outpatient settings. Among parenteral
antibiotics against M. abscessus, intravenous amikacin (AMK) is expected to be an effective outpatient antimicrobial
therapy. This study evaluated the clinical efficacy and safety of intravenous AMK therapy in outpatients with M.
abscessus pulmonary disease.
Methods: This retrospective chart review of cases of M. abscessus pulmonary disease evaluated patient background
data, AMK dosage and duration, sputum conversion, clinical symptoms radiological findings, and adverse events.
M. massiliense was excluded on the basis of multiplex PCR assay.
Results: Thirteen patients (2 men and 11 women) with M. abscessus pulmonary disease were enrolled at 2 hospitals.
The median age at the initiation of intravenous AMK treatment was 65 years (range: 50–86 years). Patients received a
median AMK dose of 12.5 mg/kg (range: 8.3–16.2 mg/kg) for a median duration of 4 months (range: 3–9 months). The
addition of intravenous AMK led to sputum conversion in 10 of 13 patients, and 8 patients continued to have negative
sputum status 1 year after treatment. Approximately half of the patients showed improvement on chest high-resolution
computed tomography. There were no severe adverse events such as ototoxicity, vestibular toxicity, and renal toxicity.
Conclusions: Thrice weekly intravenous AMK administration in outpatient settings is effective and safe for patients with
M. abscessus pulmonary disease.
Keywords: Mycobacterium abscessus, Intravenous therapy, Amikacin, Rapid-growing mycobacterium, Outpatient treatment
Background
The number of patients infected with Mycobacterium
abscessus (M. abscessus), a rapidly growing mycobacter-
ium, has been increasing recently [1, 2]. M. abscessus
pulmonary disease is one of the most difficult bacterial
infections to treat among nontuberculous mycobacterial
(NTM) diseases because of its natural resistance to most
available antibiotics. Although there are some treatment
options for M. abscessus pulmonary disease, the 2007
ATS/IDSA statement about NTM states there are no
drug regimens with proven or predictable efficacy and
that the prognosis is poor [3]. Among available antibiotics,
M. abscessus is typically sensitive to clarithromycin,
amikacin (AMK), cefoxitin, and imipenem in vitro.
Therefore, options for managing M. abscessus infection,
a chronic incurable infectious disease, are limited
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especially in outpatient settings. Among parenteral
agents, AMK is considered to be one of the most active
agents against M. abscessus infection [4].
Accordingly, the 2007 ATS/IDSA statement about NTM
mentions the clinical importance of long-term use of in-
jectable AMK [3]. Regarding persistent AMK administra-
tion, previous studies on adverse events indicate daily
systemic use can cause nephrotoxicity, ototoxicity, and
vestibular toxicity [5]. For this reason, clinical studies
on inhaled AMK aiming to overcome this clinical prob-
lem of adverse events have been initiated [6–8]. How-
ever, the practical use of intravenous AMK for patients
with M. abscessus infection is an attractive alternative,
especially in countries where inhaled AMK is not ap-
proved. Therefore, thrice weekly intravenous AMK ad-
justed according to a pharmacokinetics approach is an
option for outpatient management for this disease. Fur-
thermore, recent studies show M. massiliense exhibits
better treatment response to clarithromycin [9, 10]. How-
ever, no case series have been reported on the clinical ef-
fects of this treatment approach in precisely diagnosed
cases of M. abscessus infection, which excludes cases of
M. masilliense infection.
Therefore, this retrospective case series of M. abscessus
pulmonary disease at outpatient departments evaluated
the clinical effects of intravenous AMK therapy.
Methods
Study population and data collection
The study population consisted of patients with M.
abscessus pulmonary disease who received the combin-
ation therapy at Keio University Hospital (Tokyo, Japan)
and Fukujuji Hospital (Tokyo, Japan) from January 2004
through December 2013. The diagnosis of M. abscessus
pulmonary disease was based on the 2007 ATS/IDSA
statement [3]. Among patients with M. abscessus pulmon-
ary disease, those who received intravenous AMK therapy
for more than 3 months were enrolled. We obtained in-
formed consent from all these patients. This study was
reviewed and approved by the research ethics committees
of the Keio University School of Medicine and Fukujuji
Hospital (2011-267-2, UMIN000007546).
Amikacin administration
AMK was administered intravenously once per day thrice
weekly for 30 min via the median cubital vein. When the pa-
tients visited clinics, peripheral intravenous lines were
inserted and removed every time via the median vein. The
targeted trough level of AMK is <1 μg/mL. Regarding the
peak levels, the targeted levels is generally 56–64 μg/mL [11].
Microbiological and renal function examination
Microbiological findings from lower respiratory tract spec-
imens (i.e., sputum, bronchoalveolar lavage, and lung
biopsy) were identified. The specimens were cultured on
egg-based solid media (Kyokuto Pharmaceutical Industrial
Co., Ltd. Tokyo, Japan) or mycobacteria growth indicator
tubes (Becton, Dickinson and Co., Sparks, MD, USA). All
isolates were identified as Mycobacterium tuberculosis or
NTM by using the AccuProbe test (Gen-Probe Inc., San
Diego, CA, USA). In addition, NTM species were identi-
fied by using the DNA–DNA hybridization test (Kyokuto
Pharmaceutical Industrial Co., Ltd.). Multiplex PCR assay
was used to distinguish M. massiliense from M. abscessus
as described previously [12].
Sputum smears and cultures were evaluated 1 year
after treatment completion. Sputum conversion was de-
fined as 2 consecutive negative sputum cultures.
We also evaluated the influence of AMK administration
on renal function by measuring serum creatinine concen-
tration before treatment, 1 and 3 months after initiation of
AMK, and at the end of treatment.
Clinical symptoms
The presence/absence of fever, cough, fatigue, hemoptysis,
weight loss, night sweats, dyspnea, and sputum produc-
tion were evaluated before and after intravenous AMK ad-
ministration by retrospective chart review and inquiry
surveys to the patients following the previous study on in-
haled AMK [6].
Radiological examination
Chest high-resolution computed tomography (HRCT)
images were evaluated by a radiologist and pulmonologist
who were blinded to the clinical data. Discrepancies were
resolved by consensus review. Radiological findings after
AMK therapy were classified as “improved,” “unchanged,”
or “worse.”
Adverse events
The patients were monitored throughout the AMK ther-
apy for peak and trough levels of AMK, nephrotoxicity,
ototoxicity, and vestibular toxicity. Renal function was
assessed monthly. We do not plan ahead for follow-up
mandatory audiometry for all patients after AMK treat-
ment as a protocol, but perform audiometry according to
the physicians’ judgment, especially when the patient ad-
mitted has a hearing impairment or seek to be examined.
Statistical analysis
Summary statistics for quantitative markers are presented
as mean ± standard deviation as well as median (minimum,
maximum). Differences were analyzed by paired t-tests and
Fisher’s exact test using GraphPad Prism IV software
(San Diego, CA).
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Results
A total of 92 patients including 44 and 48 at Keio
University Hospital and Fukujuji Hospital, respectively,
who met the diagnostic criteria of the 2007 ATS/IDSA
statement for M. abscessus complex pulmonary disease,
including both M. abscessus and M. massiliense, were ini-
tially enrolled. We excluded 31 patients diagnosed with
M. massiliense pulmonary disease on the basis of multi-
plex PCR assay. Among the 61 patients with M. abscessus
pulmonary disease, 48 patients were not informed of or
did not consent to thrice weekly intravenous AMK
therapy in outpatient settings. Thus, 13 patients with
M. abscessus pulmonary disease were successfully enrolled
(Fig. 1). They did not receive AMK before the study
period. The median duration of prior treatment was
16 months (range, 0–88 months).
All patients were negative for HIV. None of the patients
were excluded during the observation period. Patient
background data are shown in Table 1. There were 2 men
and 11 women. The mean age at the initiation of intraven-
ous AMK treatment was 63.6 ± 8.5 years (range, 50–86
years). Five patients exhibited coinfection of Mycobacter-
ium avium complex (MAC) pulmonary disease. No pa-
tients underwent surgical resection of M. abscessus
lesions. Among the study population, two patients had a
smoking history (220 and 340 pack-years, respectively).
None of the patients received long-term steroid therapy
(>20 mg/day) or chest radiation. One patient with a breast
cancer received chemotherapy in the past. Three had high
soil exposure from farming and gardening. None of the
patients were admitted for renal dysfunction before the
initiation of AMK treatment (Fig. 2). All the 13 patients
underwent audiometry before AMK treatment. No re-
markable abnormal findings were obtained through the
audiometric examinations.
Although this is a retrospective case series, quite a
number of patients with pulmonary M. abscessus disease
did not receive AMK treatment. We compared patient
background between the two groups in order to evaluate
a potential bias (Additional file 1: Table S1). There were
no significant differences between the two groups except
body weight. Regarding renal function, creatinine in pa-
tients not receiving AMK was higher compared to that
in patients receiving AMK, but not significantly.
During the observation period, all patients tolerated
AMK therapy well and survived. Patients received intra-
venous AMK therapy for a median duration of 4 (range,
3–9) months. At the present, all the participants are not
receiving AMK treatment.
Intravenous AMK therapy was originally initiated at a
median dose of 15.2 (range, 13.8–16.2) mg · kg−1 · day−1
on hospitalization. The dosage was subsequently adjusted
by measuring the trough drug concentrations. The trough
level was considered the drug concentration measured just
Fig. 1 Flow diagram of patient enrollment
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before the third administration, and the peak drug con-
centration was considered that 1 h after the third adminis-
tration. In 8 patients, the trough level of AMK exceeded
1.0 μg/mL after the third administration, and the dose was
decreased by a median 20.2 % (range, 18.2–21.4 %). The
dose of AMK was also decreased in 2 of the 8 patients,
because the measured level exceeded the target trough
level even after the first dose reduction. After confirm-
ing the trough concentration was within a safe range,
the predetermined dosage of AMK was subsequently
administered at the outpatient department of the study
hospitals (n = 7) or by home doctors (n = 6) in all cases.
Patients eventually received a median dose of 12.5
(range, 8.3–16.2) mg/kg. The median peak level was
40.5 μg/mL (range, 18–72 μg/mL) after the third ad-
ministration. As we mainly monitored trough levels of
AMK as a safety measure in this study, we did not ad-
just the amount of intravenous AMK according to the
peak levels.
All patients had positive mycobacterial smear results
before starting intravenous AMK. Patients received an
average of 6.1 months of treatment for mycobacterial in-
fection before the initiation of intravenous AMK. Five
patients who had coinfection of MAC received mycobac-
terial treatment without AMK. In addition, a few patients
with M. abscessus pulmonary infection started treatment
at first without intravenous treatment. At the end of AMK
administration, 10 (77 %) of 13 patients exhibited negative
sputum culture conversion. In 8 (62 %) of 13 patients,
sputum culture remained negative for more than 1 year
since the end of AMK administration. Two patients had
subsequent positive sputum cultures at 4 and 8 months,
respectively, after an initial negative culture.
The results of the drug susceptibility testing are shown
in Additional file 2: Table S2. However, unfortunately, at
present, in Japan, 7H9, not cation-adjusted Mueller-
Hinton broth, which is recommended by the Clinical
and Laboratory Standards Institute (CLSI), has been used
in commercial drug susceptibility testing of M. abscessus.
In addition, the pH used differed from the recommended
pH (7.4) [13]. Although this result differs from the accur-
ate definition of CLSI, all the cases were susceptible to
AMK in this assay.
All patients were on a multidrug regimen when intra-
venous AMK was added. The 5 patients with coexistence
of MAC pulmonary disease and those suspected of MAC
pulmonary disease received clarithromycin, rifampicin,
and ethambutol before the initiation of intravenous AMK.
clarithromycin, sitafloxacin, and faropenem as oral agents,
and imipenem/cilastatin and meropenem as parenteral
agents were concomitantly used when intravenous AMK
was started (Table 2).
Fewer patients reported cough, sputum, dyspnea,
hemoptysis, fever, and fatigue at the end of intravenous
AMK than at baseline (Table 3). None of the patients
reported night sweats.
Seven of 13 patients exhibited improved chest HRCT
findings after intravenous AMK treatment. At baseline,
chest HRCT showed bronchiectasis and nodules, infiltra-
tion shadow, and cavities in 12, 8, and 4 patients, respect-
ively. While findings of nodules and infiltration improved
in 7 patients, bronchiectasis and cavities only improved in 1
patient after AMK treatment. Among the five patients with
coinfection of MAC, three showed improvements (cases 3,
4, and 13 in Table 2), one showed deterioration (case 9 in
Table 2), and one showed no change (case 1 in Table 2).
The two patients (cases 1 and 9) were resistant to clarithro-
mycin (minimum inhibitory concentration ≥32 μg/ml).
Table 1 Patient background data
Backgrounds (n = 13)
Age, mean ± SD (range), years 63.7 ± 8.5 (50–86)
Male/Female, no 2/11
Weight, mean ± SD (range), kg 44.7 ± 6.1 (35–56)
Smoking history, no (%) 2 (15.4)
Medical history, no (%)
Mycobacterium avium complex pulmonary disease 5 (38.5)
Pulmonary aspergillosis 2 (15.4)
Hypertension 2 (15.4)
Dyslipidemia 2 (15.4)
Chronic obstructive pulmonary disease 1 (7.7)
Sarcoidosis 1 (7.7)
Chronic sinusitis 1 (7.7)
Gastric cancer 1 (7.7)
Breast cancer 1 (7.7)
Uterine myoma 1 (7.7)
Ovarian cyst 1 (7.7)
Fig. 2 Serum creatinine concentrations before treatment, at
1 month after initiation of AMK, at 3 months after initiation of AMK,
and at the end of treatment
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Table 2 Clinical characteristics of patients with Mycobacterium abscessus receiving intravenous amikacin therapy
Case Age Body Weight (Kg) Dose of AMK (mg)/(mg/kg) Duration of AMK
therapy(months)








#1 68 37 400/10.8 6 CAM,EB,RFP CAM,EB,RFP,FAM - - Unchanged
#2 54 49. 600/12.2 3 CAM,EB,RFP,LVFX CAM,FAM,STFX + + Improved
#3 59 56 700/12.5 4 CAM,EB,RFP CAM,FAM,STFX + + Improved
#4 66 48 400/15.0 4 CAM,EB,RFP CAM,FAM,STFX + + Improved
#5 61 46 400/8.3 4 CAM,EB,RFP,SM CAM,EB,FAM,STFX + + Improved
#6 86 49 600/12.2 8 CAM,IPM/CS CAM,FAM,LVFX + - Improved
#7 50 36 500/13.9 9 - CAM,FAM,MINO + + Worsened
#8 56 40 600/15.0 4 - CAM,IPM/CS,MINO + + Improved
#9 62 52 750/14.4 4 CAM,EB,RFP,LVFX, CAM,IPM/CS,MINO + + Worsened
#10 65 46 600/13.0 4 CAM,EB,RFP,SM,STFX,FAM CAM,RFP,FAM + + Worsened
#11 69 43 700/16.2 4 - CAM,IPM/CS - - Worsened
#12 67 35 400/11.4 9 CAM,EB,RFP,SM CAM,RFP,FAM - - Unchanged
#13 65 44 400/9.1 6 CAM,EB,RFP CAM,FAM + - Improved















There were no severe adverse events such as ototox-
icity and vestibular toxicity throughout the observation
period. Of the 13 patients, 11 underwent audiometry
after AMK treatment. None of the 11 patients had re-
markable abnormal findings. The two patients who did
not undergo follow-up audiometry did not complain of
hearing disturbance after AMK treatment. Eight of 13
patients displayed the exceeded trough level of AMK
(1 μg/ml) after the third administration as described be-
fore. Serum creatinine concentration was not influenced
by AMK administration (Fig. 2).
Discussion
This study evaluates the clinical effects of thrice weekly
intravenous AMK on outpatients with M. abscessus pul-
monary disease. Intravenous AMK therapy added onto
existing regimens including clarithromycin was well tol-
erated by all patients. Furthermore, the addition of intra-
venous AMK led to negative sputum conversion in 10
(77 %) of 13 patients treated, which remained negative
in 8 patients (62 %) 1 year after treatment. Moreover, ap-
proximately half of the patients showed improvements
in chest HRCT findings. Therefore, the results suggest
long-term intravenous AMK administered in outpatient
settings is effective, safe, and clinically meaningful for M.
abscessus pulmonary disease [11].
The strategy used to adjust AMK dose in this study
should be highlighted. Peloquin et al. evaluated the tox-
icity of injectable aminoglycosides between daily and
thrice weekly administration in several patients with
NTM; in their trial using AMK 25 mg/kg thrice weekly,
ototoxicity (37 %), nephrotoxicity (15 %), and vestibular
toxicity (9 %) were highly prevalent [5]. Accordingly, the
2007 ATS/IDSA statement mentions that this dosage is
impractical for intramuscular administration and there-
fore recommends a lower dosage [3]. In the present
study, AMK administration was started at 15 mg/kg, and
the dosage was subsequently adjusted by monitoring the
trough concentration. Consequently, the median dose
decreased to 12.5 (8.3–16.2) mg/kg. In fact, more than
half of the patients underwent intravenous AMK dose
reduction. This strategy is thought to be a major reason
why no severe adverse events occurred.
Another strength of this study is the precise bacterio-
logical diagnosis of M. abscessus. M. massiliense is a
newly discovered Mycobacterium species. Unlike some
previous studies involving clinical evaluations of M.
abscessus [14–16], we evaluated strictly diagnosed M.
abscessus pulmonary disease by excluding M. massiliense
and M. bolletii using multiplex PCR assay.
The 2007 ATS/IDSA statement states negative sputum
cultures for 1 year is unlikely for the treatment of M.
abscessus. However, in the present study, negative spu-
tum conversion lasted for 1 year in more than half of
the patients; this is concordant with several other studies
on M. abscessus pulmonary disease. For example, Lyu et
al. report a case series of M. abscessus pulmonary disease
treated with daily AMK in accordance with the 2007
ATS/IDSA statement [15]; the median duration of AMK
administration was 230 (60–601) days, and 80 % of the
patients achieved negative sputum conversion. Mean-
while, in the clinical study of Jarand et al., 71 % of en-
rolled patients received intravenous AMK for a median
duration of 3 months, while 71 % of the patients exhibited
negative sputum culture conversion [14]. Thus, these
findings collectively indicate chemotherapy including
intravenous AMK can achieve a higher percentage of
sputum conversion.
In terms of susceptibility of M. abscessus in vitro, Park
et al. reported that AMK was active against most isolates
(99 %, 73/74), while imipenem (55 %, 36/66) and tobra-
mycin (36 %, 27/74) were active against a moderate
number of isolates [4]. Gayathri et al. also reported that
of 148 rapidly growing mycobacterial isolates, 146 (98 %)
were susceptible to AMK; and 138 (91 %), to gatifloxacin
[17]. Based on these in vitro studies, AMK is thought
to be the most reliable parental antibiotics against M.
abscessus. The effectiveness of tigecycline and clofazimine
has been reported recently and the synergic effects of
these agents and AMK have been reported [18–20]. The
efficacy of the combination therapy should be evaluated
in clinical studies, and the optimal treatment should be
determined.
Table 3 Clinical symptoms before and after amikacin treatment
Clinical symptom Before treatment (n = 13) After treatment (n = 13) P value*
Cough 12 (92.3 %) 9 (69.2 %) 0.027
Sputum 11 (84.6 %) 7 (53.8 %) 0.182
Dyspnea 5 (38.5 %) 2 (15.4 %) 0.114
Hemoptysis 3 (23.1 %) 0 (0.0 %) 0.004
Fever 2 (15.4 %) 1 (7.7 %) 0.009
Fatigue 2 (15.4 %) 1 (7.7 %) 0.009
Night sweat 0 (0.0 %) 0 (0.0 %) -
Data are presented as n (%) *:McNemar’s test
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Regarding chest HRCT findings, intravenous AMK
treatment improved nodules and infiltrates in half of the
patients in the present study. However, cavity and bron-
chiectasis tended to be irreversible lesions as reported in
a radiological study of NTM [21]. Actually, as shown in
Table 2, 5 out of 13 cases admitted worsened in chest
HRCT findings in spite of AMK treatment. We reevalu-
ated the clinical characteristics of the worsened cases.
The worsened cases admitted the larger extent of bron-
chiectasis and larger cavity. Although we were not able
to analyze statistically due to the small number, the ex-
tent of bronchiectasis and the size of cavity before the
initiation of AMK treatment is thought to be one of the
main factors which decides the succeed in posttreatment.
Therefore, surgical removal should be strongly considered
in operable situations, although no patients were operated
on in the present study.
The duration of intravenous AMK therapy is controver-
sial. Although long-term intravenous AMK administration
is thought to be associated with better clinical outcomes, it
could lead to a greater incidence of adverse events [21]. In
addition, thrice weekly outpatient visits for many months
would decrease patients’ quality of life. Accordingly, some
recent studies of inhaled AMK for pulmonary NTM infec-
tions indicate inhaled AMK therapy leads to successful
treatment without any evidence of systemic toxicity [6–8].
Therefore, inhaled AMK therapy is expected to be a new
approach for pulmonary NTM infections. However, as
mentioned above, inhaled AMK therapy is not approved in
many countries besides the United States and some
European countries. Nevertheless, the present results
indicate our dose-adjusted intravenous AMK approach
is very safe, practical, and feasible in countries where
inhaled AMK therapy is not approved. Beyond the
scope of this retrospective case series, successful intra-
venous AMK treatment requires home doctors to form
good relationships with their patients. Accordingly, we
asked the patients’ home doctors to prescribe the pre-
determined dosage of AMK in order to maintain treat-
ment adherence and improve patient quality of life.
In this case series, we added AMK to other agents
(faropenem, levofloxacin, etc.) simultaneously. When the
patient has worsened clinical findings or is diagnosed with
M. abscessus pulmonary disease, we considered modifica-
tion of the chemotherapy or starting chemotherapy. We
initiated AMK treatment during admission in order to ad-
just the AMK dose. As admission is suitable for the
addition of other agents, AMK was added concomitantly
to other agents just after the prior regimen.
We were unable to utilize cefoxitin, which is one of
the standard antibiotics against M. abscessus, because of
licensing issues in Japan. Accordingly, we expect the use
of cefoxitin as an initial therapy will provide additional
clinical benefits, because it is one of the few antibiotics
to which M. abscessus is susceptible. Nevertheless, we
cannot exclude the possibility of the clinical effects of
the other concomitant agents. In particular, in addition
to clarithromycin, we used combination chemotherapy
with faropenem and sitafloxacin, which are not utilized
outside Japan. Faropenem is an orally active beta-lactam
antibiotic belonging to the penem group that is reported
to exhibit considerable in vitro inhibitory activity against
56 strains of rapidly growing mycobacteria including M.
peregrinum, M. chelonae, M. fortuitum, and M. absces-
sus [22]. Interestingly, a recent in vitro study reported
that carbapenems, including faropenem, and rifampicin
exhibit a synergic effect against M. tuberculosis and M.
abscessus [23]. Accordingly, faropenem is widely used
for M. abscessus pulmonary disease empirically in Japan.
Sitafloxacin is a new a fluoroquinolone that has in vitro
and in vivo activity against MAC and Mycobacterium
leprae [24]; along with moxifloxacin, it is also reported
to be active against M. abscessus [25]. In the near future,
we plan to more comprehensively evaluate the clinical
efficacy of these kinds of agents in conjunction with
AMK.
In this retrospective study, we found five patients with
coinfection of MAC. AMK has also been reported to be
an active agent against MAC, including macrolide-resistant
MAC. Recent studies have focused on the emergence of M.
abscessus in MAC pulmonary disease [26]. Our study also
highlights that AMK is an effective and safe agent for cases
with coinfection of MAC and M. abscessus.
This study has some limitations that should be mentioned.
First, clinical symptoms were evaluated by retrospective
chart review and inquiry surveys to patients. Therefore, the
improvement of clinical symptoms may have been overesti-
mated, because we were unable to exclude recall bias. An-
other limitation is the evaluation of hearing ability as an
adverse event related to AMK. We did not mandatory per-
form audiograms or vestibular examinations as a predecided
protocol. Therefore, we may have overlooked minor de-
creases in hearing loss and vestibular toxicity. The other
limitation is the chemotherapy regimen. We added AMK to
other oral agents such as faropenem and sitafloxacin. There-
fore, we could not evaluate the effectiveness of AMK alone
against pulmonary M. abscessus diseases because of the
presence of other potent agents. As the effectiveness of tige-
cycline and clofazimine has been recently reported [18–20],
the efficacy of the combination therapy should be evaluated
in clinical studies and the optimal treatment should be
determined.
It is noteworthy that our study used AMK off-label, as
the intravenous administration of AMK is not approved
under the Japanese health insurance system at present.
To overcome this ethical issue, this study was reviewed
and approved by the respective Research Ethics Com-
mittees of Keio University School of Medicine and
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Fukujuji Hospital. We anticipate that antibiotics includ-
ing AMK, which are potent against M. abscessus, will be
approved as better treatment options in the near future.
Conclusions
Thrice weekly intravenous AMK administration in
combination with the regimen including clarithromycin
in outpatient settings is effective and safe for patients
with pulmonary M. abscessus disease.
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